India Covid vaccination drive: Meet the frontline employees who bought the primary jabs on Day 1

Earlier this month, the Drug Controller General of India (DCGI) had given its nod to Oxford/AstraZeneca’s Covishield vaccine which is manufactured by the Serum Institute of India, and the indigenously developed Covaxin from Bharat Biotech for ‘restricted emergency use’.
The vaccine will first be administered to an estimated one crore healthcare employees, and round two crore frontline employees, after which to individuals above 50 years of age, adopted by individuals youthful than 50 years of age with related comorbidities.
Following the launch of the drive, Bharat Biotech, the producer of Covaxin, stated that the corporate can pay compensation to vaccine recipients in case of any severe adversarial results skilled after receiving the shot. In the consent kind to be signed by the vaccine recipients, Bharat Biotech stated, “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres/hospitals.”
The assertion from the Covaxin producer comes after questions have been raised over the efficacy of the vaccine as its section 3 medical trials are but to be accomplished.